Daiichi Sankyo Group 5-year Business Plan
(Fiscal 2013 - 2017)

from the beginning

Daiichi Sankyo Group 5-year Business Plan (Fiscal 2013 - 2017)

• The Long View: Planning Background

1. Review of the Previous 3-Year Plan

• 2nd 3-Year Plan (FY2010-2012): Overall Review

• 2nd 3-Year Plan: Quantitative Evaluation

2. New 5-year Business Plan

• General Objectives

• Core Strategies

• Numerical Targets

3. Innovative Pharmaceuticals

• Sustainable Growth with Smooth Transition of Key Drivers

• Brand Strategy: Olmesartan

• Global Brand Strategy: Prasugrel

• Primary Efficacy Endpoint (MACE at 24 weeks)

• Global Brand Strategy: Prasugrel

• Brand Strategy: Edoxaban

• R&D Strategy

• Pipelines: Target for Approval/Launch

• Promising Projects Beyond FY2017

4. Ranbaxy

• Global Business Strategy

• The Hybrid Business

• Generate Differentiated Products (DP)

5. Regional Strategy

• Growth Strategy in Major Markets

• FY2017 Regional Sales Target (image)

• Japan: Innovative Business Growth Strategy

• Total Protection for Cardiovascular

• Generic, Vaccine, and OTC Business in Japan

• Regional Strategy: US

• Regional Strategy: India

6. Transition to a Low-cost Operating Framework

• Transition to a Low-cost Operating Framework

7. CSR

• CSR

8. Corporate Vision

• The Daiichi Sankyo Group 5 Years from Now

Contact address regarding this material

PartI Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8

• Q&A 9

• Q&A 10

• Q&A 11

• Q&A 12

PartII Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8